首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1544664

花生過敏治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Peanut Allergy Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月11日 | 出版商:

Global Market Insights Inc. | 英文 80 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在治療方案的進步以及意識和診斷不斷提高的推動下，2024年至2032年全球花生過敏治療市場規模的複合年成長率將達到12.1%。口服免疫療法和新生物製劑等創新為控制花生過敏提供了更有效、更有針對性的解決方案。此外，對這種疾病的認知的提高和診斷技術的改進導致了更高的診斷率和更大的治療需求。

這些發展確保了早期干預和更好的管理，隨著越來越多的人尋求先進且有效的花生過敏治療方案，擴大了市場。 2024 年 8 月，澳洲推出了一種針對花生過敏嬰兒的突破性口服免疫療法。該計劃由國家過敏卓越中心和默多克兒童研究所合作，在 10 家兒科醫院推出了標準化護理模式。

這項舉措凸顯了人們越來越認知到及時介入和整體護理方法的重要性。此舉可能會激勵其他國家實施類似的計劃，從而擴大花生過敏治療的全球市場並推動進一步的研究和投資。

花生過敏治療格局依給藥途徑、藥物類別、配銷通路和地理區域進行分類。

到 2032 年，口腔細分市場有望實現顯著成長，這要歸功於其方便用戶使用的管理方式以及患者對口腔治療的興趣不斷上升。口服溶液，包括免疫治療片劑和膠囊，為控制花生過敏提供了一種簡單且非侵入性的方法。這些方法有助於逐漸脫敏，並有可能持久緩解過敏反應。隨著研究和開發的不斷進步，口服療法的功效不斷提高，加上患者的強烈依從性，鞏固了其在花生過敏治療領域的領先地位。

到 2032 年，零售藥局憑藉其廣泛的影響力和消費者可及性，將鞏固其在市場上的主導地位。零售藥局提供各種非處方藥和處方藥解決方案，是應對花生過敏的人的首選。他們能夠即時提供藥物、針對過敏原的產品和量身定做的諮詢服務，從而增強了消費者之間根深蒂固的信任。這種信任與廣泛的分銷網路相結合，使零售藥局處於市場的前沿。

亞太地區預計將在花生過敏治療市場中佔據重要佔有率，預計到 2032 年複合年成長率將強勁。。人們對過敏管理的認知不斷提高，加上治療方法的突破，進一步推動了這個趨勢。此外，該地區的經濟進步轉化為醫療保健支出的增加和更廣泛的尖端治療方法。鑑於亞太地區巨大的市場潛力和迅速的進步，它成為全球花生過敏治療領域的關鍵參與者。

產業生態系統分析
產業影響力
- 成長動力
  - 花生過敏的盛行率不斷上升
  - 免疫治療的批准增加
  - 增加開發新治療方式的投資
  - 及時治療花生過敏的意識不斷提高
- 產業陷阱與挑戰
  - 免疫治療費用高昂
  - 初始治療階段的安全問題
成長潛力分析
未來市場趨勢
監管環境
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按管理途徑，2021 - 2032 年

主要趨勢
可注射
口服
其他給藥途徑

第 6 章：市場估計與預測：按藥物類別，2021 - 2032 年

主要趨勢
腎上腺素
抗組織胺藥
免疫療法
其他藥物類別

第 7 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
其他分銷管道

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Adamis Pharmaceuticals Corporation
AdvaCare Pharma
Aimmune Therapeutics Inc.
Amneal Pharmaceuticals LLC
Amphastar Pharmaceuticals, Inc.
CVS Pharmacy
DBV Technologies
Kaleo
Mylan N.V.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sanofi
TerSera Therapeutics LLC
Teva Pharmaceuticals Industries Ltd.

簡介目錄

Product Code: 10199

Global Peanut Allergy Treatment Market size will register a 12.1% CAGR from 2024 to 2032, propelled by advancements in treatment options and growing awareness and diagnosis. Innovations such as oral immunotherapy and new biologics offer more effective and targeted solutions for managing peanut allergies. Also, increased awareness about the condition and improved diagnostic techniques lead to higher diagnosis rates and a greater demand for treatment.

These developments ensure early intervention and better management, expanding the market as more individuals seek advanced and effective treatment options for peanut allergies. In August 2024, Australia unveiled a groundbreaking oral immunotherapy for infants with peanut allergies. This initiative, a collaboration between the National Allergy Centre of Excellence and Murdoch Children's Research Institute, rolled out a standardized care model across 10 pediatric hospitals.

This initiative highlights the increasing acknowledgment of the importance of timely interventions and holistic care approaches. Such a move could motivate other nations to implement comparable programs, thereby broadening the global market for peanut allergy treatments and fueling further research and investments.

The peanut allergy treatment landscape is categorized by route of administration, drug class, distribution channel, and geographical region.

The oral segment is poised for significant growth up to 2032, attributed to its user-friendly administration and the rising patient inclination towards oral therapies. Oral solutions, including immunotherapy tablets and capsules, present a straightforward and non-invasive approach to managing peanut allergies. These methods facilitate gradual desensitization, potentially offering lasting relief from allergic responses. With ongoing advancements in research and development, the heightened efficacy of oral therapies, coupled with strong patient adherence, solidifies their leading role in the peanut allergy treatment arena.

By 2032, retail pharmacies are set to cement their dominance in the market, thanks to their vast reach and consumer accessibility. Offering a diverse array of both over-the-counter and prescription solutions, retail pharmacies stand out as a go-to for those navigating peanut allergies. Their capability to provide instant access to medications, allergen-specific products, and tailored consultations fosters deep-seated trust among consumers. This trust, combined with an expansive distribution network, positions retail pharmacies at the forefront of the market.

Asia Pacific is on track to capture a significant share of the peanut allergy treatment market, with projections indicating a robust CAGR through 2032. This growth is fueled by the region's vast and growing population, a rising incidence of peanut allergies, and an evolving healthcare framework. Heightened awareness regarding allergy management, coupled with breakthroughs in treatment methodologies, further propels this trend. Moreover, the region's economic strides translate to increased healthcare expenditures and broader access to cutting-edge treatments. Given Asia Pacific's immense market potential and swift advancements, it stands as a pivotal player in the global peanut allergy treatment landscape.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of peanut allergies
  - 3.2.1.2 Increasing approvals for immunotherapeutic treatments
  - 3.2.1.3 Increasing investments for developing new treatment modalities
  - 3.2.1.4 Rising awareness towards timely treatment of peanut allergies
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of immunotherapeutic treatments
  - 3.2.2.2 Safety issues during initial treatment phase
3.3 Growth potential analysis
3.4 Future market trends
3.5 Regulatory landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Injectable
5.3 Oral
5.4 Other routes of administration

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Epinephrine
6.3 Antihistamines
6.4 Immunotherapies
6.5 Other drug classes

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Other distribution channels

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa